ArticleCells2019
miRNA-29b Inhibits Prostate Tumor Growth and Induces Apoptosis by Increasing Bim Expression.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Epigenetic regulation in a high-sugar environment (Review).International journal of molecular medicine · 2026Review
- Extracellular Vesicles from Osteotropic Triple-Negative Breast Cancer Cells Transfer miRNAs to Bone Cells Reducing Collagen Expression and Bone Matrix Mineralisation.Pharmaceutics · 2026Article
- Regulatory roles of microRNAs in signaling pathways and their biomarker potential in prostate cancer.Cancer cell international · 2026Review
- Identification of Selected Genes Associated With the Prediction of Prognosis in Bladder Cancer.Combinatorial chemistry & high throughput screening · 2026Article
- Abnormal levels of miRNA in pancreatic cancer are linked to tumor progression by regulating the translation of tumor-associated mRNA.Annals of medicine · 2025Review
- KDM3B suppresses castration-resistance prostate cancer cell proliferation by promoting PTEN expression.European journal of medical research · 2025Article
- The expression of miR-381-3p in acute myeloid leukemia and its effect on corresponding cell proliferation and apoptosis.Discover oncology · 2025Article
- A novel necroptosis-related miRNA signature for predicting the prognosis of esophageal cancer and immune infiltration analysis.Translational cancer research · 2025Article
- Downregulation of ECRG4 by DNMT1 promotes EC growth via IRF3/IFN-γ/miR-29b/DNMT1/ECRG4 positive feedback loop.iScience · 2025Article
- Knockout of a single Pax6 gene (toy but not ey) leads to compound eye deficiency and small head in honeybees.Communications biology · 2024Article
- Exploring the clinical and biological significance of the cell cycle-related gene CHMP4C in prostate cancer.BMC medical genomics · 2024Article
- Integration of photomagnetic bimodal imaging to monitor an autogenous exosome loaded platform: unveiling strong targeted retention effects for guiding the photothermal and magnetothermal therapy in a mouse prostate cancer model.Journal of nanobiotechnology · 2024Article
- miRNA‑mRNA network contributes to HBV‑related hepatocellular carcinoma via immune infiltration induced by GRB2.Biomedical reports · 2024Article
- Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study.International journal of molecular sciences · 2024Article
- Multifaceted role of microRNAs in gastric cancer stem cells: Mechanisms and potential biomarkers.World journal of gastrointestinal oncology · 2024Review
- MiR-383-5p inhibits the proliferation and migration of lung adenocarcinoma cells by targeting SHMT2.Journal of Cancer · 2024Article
- miR-4299 inhibits tumor progression in pancreatic cancer through targeting ADAM17.Molecular and cellular biochemistry · 2023Article
- MicroRNA-nanoparticles against cancer: Opportunities and challenges for personalized medicine.Molecular therapy. Nucleic acids · 2023Review
- Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.Cancers · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is one of the most common cancers among men. Currently available therapies improve patient survival against local prostate cancer but have shown severe side effects. Advanced prostate cancer is still incurable. Studies have suggested the involvement of non-coding RNAs, especially micro-RNAs (miRNAs), in the regulation of multiple cellular events in cancer and thus several clinical trials are ongoing using miRNAs mimics or inhibitors. We previously demonstrated that miRNA-29b-3p (miR-29b) was downregulated in prostate cancer and that the overexpression of miR-29b limited prostate cancer metastasis. However, the therapeutic potential of the miR-29b against prostate cancer remains unknown. Here, we evaluated the therapeutic role of miR-29b in in vivo prostate tumors in a mouse model. Intratumoral injection of mimic miR-29b significantly inhibited prostate cancer xenograft tumor growth in nude mice. Subsequent study demonstrated that the overexpression of miR-29b reduced prostate cancer cell PC3 proliferation in a time dependent manner and induced cell death. Mechanistic study using a cancer pathway specific transcriptomic array revealed a significant overexpression of the pro-apoptotic gene BCL2L11 (Bim) in the miR-29b overexpressed PC3 cells, which was further verified in PC3 cells overexpressing miR-29b. We also observed a significant induction of Bim protein in miR-29b treated xenograft tumors. The induction of cytosolic accumulation of cytochrome C and PARP cleavage in miR-29b overexpressed PC3 cells was observed. Thus, our results suggest that miR-29b can be used as a potential molecule for prostate cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.